Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ocular ointment or steroid ointment versus placebo after intravitreal injection for post-procedural eye pain
MOH_2024-01-22_013202Phase 3Not yet recruiting
- Sponsor
- ד"ר טארק גאעוני
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in Ocular pain is not a disease; it is a symptom. The canonical disease entity most closely related to persistent, unexplained ocular pain is "ocular neuropathic pain" or "neuropathic ocular pain" comparing Lakripos Gel, Maxitrol and Placebo (3 arms). Primary endpoints: Duration of eye pain after intravitreal injection and Intensity of eye pain after intravitreal injection. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
dexamethasone + neomycin + polymyxin BLakripos
03
Conditions
Ocular pain is not a disease; it is a symptom. The canonical disease entity most closely related to persistent, unexplained ocular pain is "ocular neuropathic pain" or "neuropathic ocular pain".
Beyond the preview
Go deeper on MOH_2024-01-22_013202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-22_013202.